How is ketamine used to treat treatment‑resistant depression, including dosing, administration, contraindications, and side effects?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ketamine for Treatment-Resistant Depression

Ketamine and esketamine are now recommended treatment options for patients with treatment-resistant depression who have failed at least 2 adequate antidepressant trials, representing a major shift from the 2016 guideline that recommended against ketamine use outside research settings. 1

Patient Selection and Indications

Reserve ketamine/esketamine for patients who have not responded to several adequate pharmacologic trials—not as initial treatment. 1 The evidence specifically supports use in patients with major depressive disorder (MDD) for whom at least 2 previous adequate trials of antidepressant medications have failed 1.

Key Contraindications

  • Patients for whom significant blood pressure elevation would constitute a serious hazard 2
  • Known hypersensitivity to ketamine 2
  • Patients at risk for increased intracranial pressure 3

Dosing and Administration

Intravenous Ketamine

Standard dosing: 0.5 mg/kg administered intravenously over 40 minutes 1, 4

Frequency options:

  • Twice-weekly dosing: Maintains antidepressant efficacy over 15 days with similar effectiveness to thrice-weekly 4
  • Thrice-weekly dosing: Also effective, though no superior benefit over twice-weekly 4

Important administration details:

  • Must be administered by physicians experienced in general anesthetics, airway management, and ventilation 2
  • Do NOT inject the 100 mg/mL concentration intravenously without proper dilution 2
  • Dilute with equal volume of Sterile Water, Normal Saline, or 5% Dextrose 2
  • Administer slowly over 60 seconds to avoid respiratory depression and enhanced vasopressor response 2

Intranasal Esketamine

Twice-weekly dosing as augmentation to ongoing oral antidepressant improves depressive symptoms and remission rates at up to 28 days 1. Unlike ketamine, esketamine has FDA Risk Evaluation and Mitigation Strategy (REMS) requirements including:

  • Pharmacy and healthcare setting certification
  • Mandatory 2-hour post-treatment monitoring 1

Timeline of Effects

Rapid onset is the hallmark advantage:

  • Significant improvement in depressive symptoms within 24 hours 1
  • Effects persist at 3-4 day follow-up 1
  • When added to ongoing antidepressant: significant improvements up to 7 days 1
  • When used as monotherapy: no significant differences at 7 days 1

This rapid action also extends to suicidal ideation, with ketamine supported as adjunctive treatment for short-term reduction in suicidal ideation 1.

Critical Safety Monitoring

Cardiovascular Effects

Blood pressure monitoring is mandatory. Transient increases in systolic and diastolic blood pressure are dose-dependent, beginning shortly after administration and peaking at 30-50 minutes, with rises of 10-50% above predose values 3.

Required monitoring protocol:

  • Assess blood pressure prior to each dose 3
  • Hypertensive patients must receive effective management before treatment 3
  • Monitor continuously after administration until blood pressure returns to acceptable levels 3
  • If blood pressure remains elevated, provide acute management 3
  • Hypertensive crisis requires immediate emergency care 3

Neuropsychiatric Effects

Dissociative symptoms occur transiently and attenuate with repeated dosing 4. The most common treatment-emergent adverse events (≥20%) include:

  • Headache
  • Anxiety
  • Dissociation
  • Nausea
  • Dizziness 4

Emergence reactions (postoperative confusional states, agitation, vivid imagery, hallucinations) occur in approximately 12% of patients during recovery, generally lasting a few hours 2. To mitigate:

  • Consider adjunctive benzodiazepine administration 2
  • Minimize verbal, tactile, and visual stimulation during recovery 2

Other Safety Considerations

  • Continuous vital sign monitoring required 2
  • Emergency airway equipment must be immediately available 2
  • Risk of respiratory depression with overdosage or rapid administration 2
  • Vomiting and aspiration may occur despite active laryngeal-pharyngeal reflexes 2
  • Administer antisialagogue prior to induction due to salivation potential 2

Genitourinary Concerns

In individuals with chronic ketamine use for off-label indications, case reports document genitourinary pain potentially related to treatment 2. Consider cessation if genitourinary pain continues with other genitourinary symptoms 2.

Critical Limitations

The major gap is long-term data. Ketamine lacks long-term efficacy and safety trials in MDD, with bulk of evidence limited to short-term (7-day) efficacy 1. While evidence supports longer-term maintenance use of esketamine, it too has been primarily studied in patients who previously failed antidepressant trials 1.

Important caveat: The effectiveness of esketamine in preventing suicide or reducing suicidal ideation/behavior has NOT been established, despite FDA approval for depressive symptoms in adults with MDD and acute suicidal ideation or behavior 1.

Clinical Decision Algorithm

  1. Confirm TRD diagnosis: At least 2 adequate antidepressant trials have failed
  2. Screen for contraindications: Cardiovascular risk assessment, hypertension control, hypersensitivity history
  3. Optimize blood pressure before initiating treatment
  4. Choose formulation:
    • IV ketamine: 0.5 mg/kg over 40 minutes, twice-weekly preferred for balance of efficacy and burden
    • Intranasal esketamine: If REMS-certified facility available, twice-weekly with ongoing antidepressant
  5. Implement safety monitoring: Continuous vital signs, 2-hour post-treatment observation minimum
  6. Assess response at 24 hours and days 3-4
  7. Plan maintenance strategy: Evidence supports continuation, but optimal duration undefined
  8. Monitor for adverse effects: Particularly cardiovascular, dissociative, and genitourinary symptoms

The recommendation reflects consistent evidence of benefit balanced against risks and limited long-term data 1. Additional information about long-term outcomes will be particularly beneficial for future evaluations 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.